Open company graph database — free web & API
Login

EN Otsuka Pharmaceutical Co., Ltd.

イーエヌ大塚製薬株式会社Otsuka Pharmaceutical Co., Ltd.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
6,070
Related companies
87
§01

Basic information

BASIC
Head office
3-5, 4th Division, Nimai-bashi, Hanamaki-shi, Iwate Prefecture, 025-0312Sources
Chief executive
Hiroshi HashikawaSources
Capital
1,510,000,000  (15 100 million)
Employees (non-consolidated)
424 people
Employees (consolidated)
6,070 people
Start date
2002-03-26
End date
§02

Websites

3 DOMAINS
§03

Business

1
Research, development, manufacturing, sales, and import/export of enteral nutrition products, medical foods, foods for the elderly, and various foods for patientsSources
§04

Related companies

87 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Otsuka Holdings Co., Ltd. SourcesSources
Group Parent
Otsuka Pakistan Ltd. Sources
Group
Arab Otsuka Nutraceuticals Corporation Sources
Group
Otsuka America Pharmaceutical, Inc
Group
PT Amertain Da Otsuka Sources
Group
PT Otsuka Indonesia Sources
Group
Interpharma Prague a.s. Sources
Group Subsidiary
Cambridge Isotope Laboratories Inc. Sources
Group
Nutrition et Santé SAS Sources
Group Subsidiary
McQuaid Center for Strategic Research and Development LLC Sources
Group
Otsuka Nigeria Neutral Therapeutic Company Ltd. Sources
Group
Otsuka Pharmaceutical Factory America Inc.
Group
Otsuka Pharmaceutical Europe Ltd.
Group
Crystal Geyser Water Company Sources
Group
Otsuka Pharmaceuticals (U.K.) Ltd. Sources
Group Subsidiary
Otsuka Pharmaceutical S.A. Sources
Group Subsidiary
Otsuka Pharmaceutical (Switzerland) GmbH Sources
Group Subsidiary
Otsuka Pharmaceutical Netherlands BV Sources
Group Subsidiary
Otsuka Pharma Scandinavia AB Sources
Group Subsidiary
Otsuka Electronics Co., Ltd. Sources
Group
Nardobel SAS Sources
Group Subsidiary
PT Otsuka Distribution Indonesia Sources
Group
Pharmavite LLC
Group
Abdi Ibrahim Otsuka Pharmaceutical Co., Ltd. Sources
Group
PharmaByte LLC Sources
Group
Farma Bite (Shanghai) Health Technology Co., Ltd. Sources
Group
China Otsuka Pharmaceutical Co., Ltd. Sources
Group
Otsuka (Philippines) Pharmaceuticals Inc. Sources
Group
Otsuka (China) Investment Co., Ltd. Sources
Group
Otsuka Canada Pharmaceuticals Inc. Sources
Group
Otsuka Solar Philippines Inc. Sources
Group
Otsuka Digital Health Co., Ltd. Sources
Group
Otsuka Nutraceutical Mexico Co., Ltd. Sources
Group Subsidiary
Otsuka Nutraceutical (Thailand) Co., Ltd. Sources
Group
Otsuka Nutra Therapeutic India Co., Ltd. Sources
Group
Otsuka Nutraceutical Vietnam Ltd. Sources
Group
Otsuka Nobel Products GmbH Sources
Group Subsidiary
Otsuka Pharma GmbH Sources
Group Subsidiary
Otsuka Pharmaceutical D&C Inc. Sources
Group
Otsuka Pharmaceutical Italy S.r.l. Sources
Group Subsidiary
Otsuka Pharmaceutical France SAS Sources
Group Subsidiary
Otsuka Pharmaceutical Europe Ltd. Sources
Group Subsidiary
Otsuka Myanmar Co., Ltd. Sources
Group
Otsuka Medical Devices Co., Ltd. SourcesSources
Group Subsidiary
Otsuka Pharmaceutical (Malaysia) Co., Ltd. Sources
Group
Otsuka Pharmaceutical Research (Beijing) Co., Ltd. Sources
Group
Otsuka Foods Co., Ltd. SourcesSources
Group Subsidiary
Tianjin Otsuka Beverage Co., Ltd. Sources
Group
Zhejiang Dazhong Pharmaceutical Co., Ltd. Sources
Group
Korea Otsuka Electronics Co., Ltd. Sources
Group
Otsuka Australia Pharmaceuticals Pty Ltd. Sources
Group
Toa Otsuka Corporation Sources
Group
Nihon Rika Chemical Industry Co., Ltd. Sources
Group
Taio Otsuka Pharmaceutical Co., Ltd. Sources
Group
Otsuka Warehouse Co., Ltd. SourcesSources
Group Subsidiary
Otsuka Chemical Co., Ltd. SourcesSources
Group Subsidiary
Otsuka Pharmaceutical Korea Co., Ltd. Sources
Group
Junana Therapeutics Inc. Sources
Group
Tokushima Voltics Co., Ltd. Sources
Group
King Car Da Tsu Co., Ltd. Sources
Group
A&P Inphatec, LLC Sources
Group
Otsuka America, Inc. Sources
Group
Otsuka America Pharmaceutical Inc. Sources
Group
CG Roxane LLC Sources
Group
Daipon Pharmaceutical Industries Co., Ltd. SourcesSources
Group Subsidiary
Astex Therapeutics Ltd. Sources
Group Subsidiary
Earth Corporation Sources
Group
Daiya Foods Inc. Sources
Group
Earth Environmental Services Co., Ltd. Sources
Group
Visterra, Inc. Sources
Group
Kitasato Otsuka Biomedical Assay Institute Inc. Sources
Group
Bonafide Health LLC Sources
Group
Ridge Vineyards Inc. Sources
Group
Heartful Sendai Corporation Sources
Group
アルマ S.A. Sources
Group Subsidiary
FoodState Inc. Sources
Group
台湾大塚製薬股份有限公司 Sources
Group
Sichuan Otsuka Pharmaceutical Co., Ltd. Sources
Group
Otsuka Wellness Bending Co., Ltd. Sources
Group
大塚シンガポール Pte.Ltd. Sources
Group
Otsuka Nutraceutical Emerging Venture LLC Sources
Group
大塚プレシジョンヘルス Inc Sources
Group
Otsuka Mechatronics Co., Ltd. Sources
Group
大塚慎昌(広東)飲料有限公司 Sources
Group
大塚製薬(シンガポール)株式会社 Sources
Group
広東大塚製薬有限公司 Sources
Group
Hong Kong Otsuka Pharmaceutical Co., Ltd. Sources
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

23 EVENTS

Founded in Naruto City, Tokushima Prefecture as a chemical raw material manufacturerSources

Started an intravenous infusion (IV) business and entered the pharmaceutical businessSources

Launched a consumer health drink (Oronamin C Drink) and entered the nutraceuticals businessSources

Otsuka Pharmaceutical established its first in‑house pharmaceutical research laboratory as part of the Otsuka GroupSources

Pursued its first overseas expansion with the aim of contributing to the health of people worldwideSources

Otsuka Skin Care Research Institute was established in 1990Sources

Otsuka Nutrition Science Institute (Otsuka Research Site) was established in 2000Sources

Eliquis® (generic name: apixaban) was approved in the United States in 2002 as a medication for schizophreniaSources

Established Otsuka Holdings as a pure holding company of the groupSources

Samska®/Jinark (generic name: tolbutamide) was launched in Europe and the United States in 2009Sources

Samska®/Jinark was launched in Japan in 2010Sources

Listed on the First Section of the Tokyo Stock ExchangeSources

Samska®/Jinark was approved in Japan in 2014 as the first drug worldwide to suppress the progression of ADPKDSources

Samska®/Jinark was approved in Europe in 2015Sources

Bonafide Health was established in 2017Sources

Samska®/Jinark was approved in the United States in 2018Sources

In 2020, the "Otsuka Group Human Rights Policy" was formulatedSources

100th anniversary of foundingSources

Transitioned to the Prime market of the same exchangeSources

Lexalt® was approved in the United States in 2023 as the first drug with an indication for this conditionSources

Lexalt® was approved in Japan in 2024 as the first drug with an indication for this conditionSources

In 2024, the company welcomed Junana Corp. into its group, incorporating low‑molecular‑weight drug discovery technologySources

Sibeprelumab (generic name) received accelerated approval in the United States in 2025 as a treatment for adult IgA nephropathySources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information7010001012986
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
大塚製薬株式会社
Trade name (kana)
オオツカセイヤク
Name in English
Corporation type
301
Address
〒101-0048 東京都千代田区神田司町2丁目9番地
Postal code
1010048
Prefecture code
13
City code
101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-26
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2163197
METI gBizINFO7010001012986
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7010001012986
Trade name
大塚製薬株式会社
Trade name (kana)
オオツカセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都千代田区神田司町2丁目9番地
Postal code
1010048
Prefecture
東京都
Prefecture code
13
City or district
千代田区
City code
101
Street address
神田司町2丁目9番地
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役 井上 眞
Capital
Employees
5761
Employees (male)
4478
Employees (female)
1592
Business summary
医薬品・臨床検査・医療機器・食料品・化粧品の製造、製造販売、販売、 輸出ならびに輸入
Website URL
https://www.otsuka.co.jp/
Year founded
Business category
E:製造業
Date established
1964-08-10
Unified government qualification - grade
|A|A|
Unified government qualification - business items
229|303|315
Update date
2018-04-26
Key information
7010001012986
§09

Sources & updates

SOURCES
↑